Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 17, 2023

SELL
$62.32 - $89.47 $16,577 - $23,799
-266 Reduced 1.35%
19,504 $0
Q3 2022

Oct 12, 2022

BUY
$59.54 - $68.01 $1,250 - $1,428
21 Added 0.11%
19,770 $1.22 Million
Q2 2022

Jul 20, 2022

BUY
$57.72 - $65.01 $71,976 - $81,067
1,247 Added 6.74%
19,749 $1.22 Million
Q1 2022

Apr 18, 2022

BUY
$57.92 - $72.58 $59,599 - $74,684
1,029 Added 5.89%
18,502 $1.1 Million
Q4 2021

Jan 20, 2022

BUY
$64.88 - $73.64 $50,606 - $57,439
780 Added 4.67%
17,473 $1.27 Million
Q3 2021

Oct 20, 2021

BUY
$67.69 - $73.03 $11,507 - $12,415
170 Added 1.03%
16,693 $1.17 Million
Q2 2021

Jul 19, 2021

BUY
$63.47 - $69.35 $500,207 - $546,547
7,881 Added 91.19%
16,523 $1.14 Million
Q1 2021

Apr 27, 2021

BUY
$60.0 - $68.46 $518,520 - $591,631
8,642 New
8,642 $559,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Donald L. Hagan, LLC Portfolio

Follow Donald L. Hagan, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Donald L. Hagan, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Donald L. Hagan, LLC with notifications on news.